IndustryCompany release

Cognizant narrows 2026 revenue guidance and extends Gilead Sciences partnership by five years

🇺🇸 Cognizant Technology Solutions Corp (CTSH) · Thu 29 Oct 2026

The technology services provider reported third-quarter revenue of $5.66 billion, raised its Project Leap restructuring cost estimate and announced a five-year extension of its work with Gilead Sciences.

Cognizant Technology Solutions reported third-quarter 2026 results on 29 October. Revenue was $5.66 billion, up 4.6% on the year according to the company's headline. GAAP diluted earnings per share were $1.39, and adjusted earnings per share were $1.49.

For the full year, Cognizant narrowed its revenue growth guidance to 4.0%-4.4% in constant currency. It set adjusted EPS guidance at $5.72-$5.79.

The company also raised its estimate of the cost of its Project Leap restructuring programme to $180-$250 million. The material available to VigiEye does not detail the programme's scope or timing.

For the life sciences sector, the main item is the announced five-year extension of Cognizant's work with Gilead Sciences. The summary on file does not describe which services the extension covers, its financial value or its start date.

What it means for your team

  • Teams at pharma companies that rely on Cognizant for technology services should check with their account managers whether Project Leap affects delivery or staffing on their contracts. The company has not said it will.
  • The Gilead extension shows that multi-year technology services arrangements remain in use in the pharma sector. Its scope has not been disclosed, so it should not be read as a signal for any particular function.
  • Vendor-oversight and quality teams may want to confirm that contract and change-control provisions cover any restructuring-driven changes at their suppliers.

Company's press release (SEC filing): Cognizant Technology Solutions Corp ↗

Article written by VigiEye from the official source (Cognizant Technology Solutions Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →